Quarterly Result30 May 2026, 04:01 pm
Titan Biotech Approves Audited Financial Results for FY26
AI Summary
Titan Biotech Ltd's Board of Directors approved the audited financial results for the year ended March 31, 2026, on May 30, 2026. The board has recommended a dividend of ₹0.50 per equity share, subject to shareholder approval. Additionally, the re-appointment of M/s Sanjay Kumar Garg & Associates as Cost Auditor was approved, pending shareholder ratification of remuneration. Mr. Pankaj Kumar Gupta was appointed as the Scrutinizer for the upcoming Annual General Meeting.
Key Highlights
- Audited financial results for FY26 approved by the Board on May 30, 2026.
- Dividend of ₹0.50 per equity share recommended, subject to shareholder approval.
- M/s Sanjay Kumar Garg & Associates re-appointed as Cost Auditor, remuneration subject to shareholder ratification.
- Mr. Pankaj Kumar Gupta appointed as Scrutinizer for the 34th Annual General Meeting.
Price Impact
More from TITANBIO